Optimal glucose control in type 2 diabetes mellitus—a guide for the family practitioner

References

• Kahn SE. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000; 108(suppl 6a): 2s–8s.
   PubMedGoogle Scholar
• United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and the risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with Metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–6.
   PubMed Web of Science ®Google Scholar
• Elvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated haemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421–31.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Position statement: Standards of medical care in diabetes—2006. Diabetes Care 2006; 29(suppl 1): s4–42.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Post-prandial blood glucose (Consensus statement). Diabetes Care 2001; 24: 775–8.
   PubMed Web of Science ®Google Scholar
• Department of Health, Republic of South Africa. National guideline: Management of diabetes type 1 and type 2 in adults at hospital level, 2005. p. 7–8.
   Google Scholar
• SEMDSA guideline:.
   Google Scholar
• Karter AJ, Ackerson LM, Darbinian JA, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med 2001; 111(1): 1–9.
   PubMed Web of Science ®Google Scholar
• Welschen LM, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care 2005; 28(6): 1510–7.
   PubMed Web of Science ®Google Scholar
• Martin S, Schneider B, Heinemann L, et al. Self-monitoring of blood glucose in type 2 diabetes and long term outcome: an epidemiological cohort study. Diabetologia 2005; 49: 271–8.
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Edelman S. Insulin therapy in type 2 diabetes. Endocrin Metab Clin North Am 2001; 30(4): 935–82.
   PubMed Web of Science ®Google Scholar
• Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25(2): 275–8.
   PubMed Web of Science ®Google Scholar
• Cagliero E, Levina EV, Nathan DM. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin- treated type 2 diabetic patients. Diabetes Care 1999; 22(11): 1785–9.
   PubMed Web of Science ®Google Scholar
• Thaler LM, Ziemer DC, Gallina DL, et al. Diabetes in urban African-Americans. XVII. Availability of rapid HbA1c measurements enhances clinical decision-making. Diabetes Care 1999; 22(9): 1415–21.
   PubMed Web of Science ®Google Scholar
• Panzer S, Kronik G, Lechner K, Bettelheim P, Neumann E, Dudczak R. Glycosylated hemoglobins (GHb): an index of red cell survival. Blood 1982; 59(6): 1348–50.
   PubMed Web of Science ®Google Scholar
• Polgreen PM, Putz D, Stapleton JT. Inaccurate glycosylated hemoglobin A1C measurements in human immunodeficiency virus-positive patients with diabetes mellitus. Clin Infect Dis 2003; 37: e53.
   PubMed Web of Science ®Google Scholar
• Fluckiger R, Harmon W, Meier W, et al. Hemoglobin carbamylation in uremia. N Engl J Med 1981; 304: 823.
   PubMed Web of Science ®Google Scholar
• Howe-Davies S, Simpson RW, Turner RC. Control of maturity-onset diabetes by monitoring fasting blood glucose and body weight. Diabetes Care 1980; 3(5): 607–10.
   PubMed Web of Science ®Google Scholar
• Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997; 20(12): 1822–6.
   PubMed Web of Science ®Google Scholar
• Sheard NF, Clark NG, Brand-Miller JC, et al. Dietary carbohydrate (amount and type) in the prevention and management of diabetes: a statement of the American Diabetes Association. Diabetes Care 2004; 27: 2266–71.
   PubMed Web of Science ®Google Scholar
• Wing RR, Blair EH, Bononi P, et al. Caloric restriction per se is a significant factor in improvements in glycaemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 1994; 17: 30.
   PubMed Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study group (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylureas, insulin, or Metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310: 83.
   Google Scholar
• Klein S, Sheard NF, Pi-Sunyer X, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004; 27: 2067–73.
   PubMed Web of Science ®Google Scholar
• Norris SL, Zhang X, Avenell A, et al. Long-term effectiveness of lifestyle and behavioural weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med 2004; 117: 762.
   PubMed Web of Science ®Google Scholar
• Cooppan R. The changing model of insulin use in type 2 diabetes. Techniques, tactics for getting to goal. Postgrad Med 2003; 113(6): 59–64.
   PubMed Web of Science ®Google Scholar
• South African National Department of Health. Standard treatment guidelines and essential drug list for South Africa: Primary health care, 2003.
   Google Scholar
• Lebovitz HE. Insulin secretagogues: Sulphonylureas, Repaglinide and Nataglanide. Therapy for diabetes mellitus and related disorders, 4th ed. American Diabetes Association, 2004. p. 164–75.
   Google Scholar
• Bailey CJ. Metformin. Therapy for diabetes mellitus and related disorders. 4th ed. American Diabetes Association, 2004. p. 176–91.
   Google Scholar
• Lebovitz HE. Thiazolinediones. Therapy for diabetes mellitus and related disorders. 4th ed. American Diabetes Association, 2004. p. 198–206.
   Google Scholar
• Rabasa-Lhoret R, Chiasson JL. α-Glucosidase inhibitors in the treatment of hyperglycemia. Therapy for diabetes mellitus and related disorders. 4th ed. American Diabetes Association, 2004. p. 192–7.
   Google Scholar
• United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: A 6-year randomized, controlled trial comparing sulphonylurea, insulin and Metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128: 165.
   PubMed Web of Science ®Google Scholar
• Wolfenbuttel BHR, Heine RJ. Behandeling van tipe 2 diabetes. In: Heine RJ, Tack CJ. Handboek diabetes mellitus. 3rd ed. Utrecht, De Tijdstroom, 2004. p. 95.
   Google Scholar
• Evans JL, Rushakoff RJ. Oral pharmacological agents for type 2 diabetes: sulphonylureas, Meglitinides, Metformin, Thiazolinediones, α-glycosidase inhibitors, and emerging approaches. Chapter 16, Endotext.com, August 2002. (http://www.endotext.org/diabetes/diabetes16/diabetesframe16.htm)
   Google Scholar
• UK Prospective Diabetes Study Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249–58.
   PubMed Web of Science ®Google Scholar
• Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. Induction of long term glycaemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997; 20: 1353–6.
   PubMed Web of Science ®Google Scholar
• Karvestedt L, Anderson G, Efendic S Grill V. A rapid increase in beta-cell function by multiple insulin injections in type 2 diabetic patients is not further enhanced by prolonging treatment. J Intern Med 2002; 251: 307–16.
   PubMed Web of Science ®Google Scholar
• Douek IF, Allen SE, Ewings P, Gale EAM, Bingley PJ. Continuing Metformin when starting insulin in patients with type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabetic Medicine 2005; 22(5): 634–40.
   PubMed Web of Science ®Google Scholar
• Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 182–8.
   PubMed Web of Science ®Google Scholar
• Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes. Diabetes Care 2005; 28: 260–5.
   PubMed Web of Science ®Google Scholar
• Hirsch IB. Intensifying insulin therapy in patients with type 2 diabetes mellitus. Am J Med 2005; 118(Suppl 5A): 21s–6s.
   PubMed Web of Science ®Google Scholar
• Skyler JS. Insulin therapy in type II diabetes. Postgrad Med 1997; 101(2): 85–90S.
   PubMed Web of Science ®Google Scholar
• Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician 2004; 70: 489–500.
   PubMed Web of Science ®Google Scholar
• Riddle MC. Making the transition from oral to insulin therapy. Am J Med 2005; 118(Suppl 5A): 14s–20s.
   PubMed Web of Science ®Google Scholar
• Yiki Jarvinen H, Ryysy L, Nikkila K, Tolokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomised controlled trial. Ann Intern Med 1999, 130: 389–96.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycaemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28(4): 950–5.
   PubMed Web of Science ®Google Scholar
• Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of glycaemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28(6): 1282–8.
   PubMed Web of Science ®Google Scholar
• Polonski KS, Given DB, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin dependent diabetes mellitus. N Eng J Med 1988; 318: 1231–58.
   PubMed Web of Science ®Google Scholar
• Monnier L Lapinski H, Colette C. Contributions of fasting and plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003; 26: 881–5.
   PubMed Web of Science ®Google Scholar
• Perriello G, Pampanelli S, Porcellati F, et al. Insulin aspart improves meal time glycaemic control in patients with type 2 diabetes: a randomized, stratified, double-blind and cross-over trial. Diabetic Medicine 2005; 22(5): 606–11.
   PubMed Web of Science ®Google Scholar
• Raskin, P. Comparison of twice-daily biphasic insulin aspart 70/30 with once-daily insulin glargine in patients with type 2 diabetes mellitus on oral antidiabetic agents. Poster 602, presented at: 64th Annual Meeting of the American Diabetes Association, June 5, 2004, Orlando, FL, USA.
   Google Scholar
• Halimi S, Raskin P, Liebl A, Kawamori R, Fulcher G, Yan G. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clinical Therapeutics 2005; 27(suppl B): s57–s74.
   PubMed Web of Science ®Google Scholar
• Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006; 66(1): 31–49.
   PubMed Web of Science ®Google Scholar
• Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice daily premixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med 2005; 22(4): 374–81.
   PubMed Web of Science ®Google Scholar
• Garber A, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1–2–3 study). Diabetes, Obesity & Metabolism 2006; 8: 58–66.
   PubMed Web of Science ®Google Scholar
• Goldman-Livine JD, Lee KW. Insulin detemir—a new basal insulin analog. Annals of Pharmacotherapy 2005; 39(3): 502–7.
   PubMed Web of Science ®Google Scholar
• Glaser B, Cerasi E. Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes. Diabetes Obes Metab 1999; 1: 67–74.
   PubMed Web of Science ®Google Scholar
• Monniere L, Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes & Metabolism 2006; 32(1):7–13S.
   PubMed Web of Science ®Google Scholar
• Alberti G: The DAWN (Diabetes Attitudes, Wishes and Needs) study. Pract Diabetes Int 2002; 19: 22–4.
   Google Scholar
• Haque M, Emerson SH, Dennison DR, Navsa M, Levitt NS. Barriers to initiating insulin therapy in patients with type 2 diabetes mellitus in public-sector primary health care centres in Cape Town. S Afr Med J 2005; 95(10): 798–802.
   PubMed Web of Science ®Google Scholar